Clinical features of neuroendocrine prostate cancer.
暂无分享,去创建一个
O. Elemento | A. Sboner | H. Beltran | J. Mosquera | K. Ballman | V. Conteduca | B. Faltas | S. Tagawa | A. Molina | D. Nanus | M. Sigouros | K. Eng | R. Bareja | C. Oromendia | Michael Sigouros
[1] Yi Mi Wu,et al. Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.
[2] A. D'Amico,et al. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. , 2019, Journal of the National Comprehensive Cancer Network : JNCCN.
[3] M. Gleave,et al. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity , 2019, Molecular Cancer Research.
[4] Joshua M. Stuart,et al. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Thomas Wiegel,et al. Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. , 2018, European urology.
[6] Michael D. Nyquist,et al. Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.
[7] N. Navin,et al. The aggressive variant prostate carcinoma (AVPC) molecular signature (-MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC). , 2017 .
[8] Henry W. Long,et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.
[9] M. Rubin,et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.
[10] Alessandro Romanel,et al. Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care , 2016, npj Genomic Medicine.
[11] Matteo Benelli,et al. Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.
[12] K. Baggerly,et al. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers , 2015, Clinical Cancer Research.
[13] Vladimir Vacic,et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.
[14] M. Rubin,et al. Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.
[15] M. Rubin,et al. Aggressive Variants of Castration-Resistant Prostate Cancer , 2014, Clinical Cancer Research.
[16] P. Thall,et al. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer , 2013, Clinical Cancer Research.
[17] M. Rubin,et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Gerstein,et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.
[19] S. Culine,et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] B. Escudier,et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] J. Epstein,et al. Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases , 2008, The American journal of surgical pathology.
[22] T. Golub,et al. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.
[23] P. Thall,et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] A. Jemal,et al. Cancer statistics, 2018 , 2018, CA: a cancer journal for clinicians.